Search Results: Treatment + Prostate Cancer + Newly Diagnosed (2 results)

This study is testing a new medication called saruparib (AZD5305) to see if it can help people with prostate cancer that is high risk for getting worse or spreading to other parts of the body. Saruparib is a type of targeted therapy known as a PARP inhibitor. The study is open to people with a BRCA1 or BRCA2 mutation in their tumor. The goal of this study is to find out if adding saruparib after radiation treatment can lower the chances of the cancer coming back or spreading.

This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.